Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

53.42 +3.00 (+5.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,596,213
Open 52.39
Bid (Size) 47.90 (1)
Ask (Size) 54.00 (3)
Prev. Close 50.42
Today's Range 52.16 - 53.55
52wk Range 46.12 - 58.10
Shares Outstanding 1,250,690,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes
The companies' shot was more than 93% effective in previously infected people. 
Via Investor's Business Daily
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24
Reuters 
Via Benzinga

Performance

YTD
+5.39%
+5.39%
1 Month
-3.75%
-3.75%
3 Month
+3.07%
+3.07%
6 Month
+5.78%
+5.78%
1 Year
+0.96%
+0.96%

More News

Read More
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
Via Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
Via Benzinga
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
Via Benzinga
Jupiter Wellness Believes Its Latest Strategic Acquisition Could Be A Significant Boon To Compete In The Medical Cannabis Industry
Via Benzinga
Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes
Via InvestorPlace
Clovis Oncology (CLVS) Stock Rallies on Buyout Rumors
Via InvestorPlace
Morning Brief: Top Financial Stories Dominating on Monday, June 13
Via Benzinga
Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern
Via Benzinga
We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit
Via Investor's Business Daily
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
Via AB Newswire
Exposures Product Safety
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Via Benzinga
U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children
Via Benzinga
CStone Pharma Replaces Chairman Amid Huge Losses, Irregular Investment
Via Benzinga
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
Exposures Product Safety
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Via Benzinga
Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer
Via Investor's Business Daily
3 Biotech Stocks to Buy Before They Boom
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Via Benzinga
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
Via FinancialNewsMedia
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Via Benzinga
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
7 Penny Stocks With 10x Potential This Year
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.